Dupixent improves esophageal function and reduces inflammation in eosinophilic esophagitis Phase 4 trial

Dupixent (dupilumab) demonstrated significant improvements in esophageal distensibility and reduced structural damage and inflammation in adults with eosinophilic esophagitis (EoE) after 24 weeks, compared to placebo. This Phase 4 REMODEL trial confirms Dupixent's role in addressing the underlying type 2 inflammation that drives EoE, a chronic disease causing esophageal narrowing and swallowing difficulties. The treatment showed benefits comparable to esophageal dilation procedures, potentially modifying disease progression and improving patient quality of life. Ongoing studies will assess long-term effects on esophageal scarring and narrowing.